Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity (2013 - 2026)

Ocular Therapeutix has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $671.3 million in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $671.3 million, up 48.74% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.6 billion (up 45.26% YoY), and the FY2025 annual result was $808.1 million, up 76.46% from the prior year.
• Liabilities and Shareholders Equity fell to $671.3 million in Q2 2026, from $732.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $808.1 million in Q4 2025 and troughed at $122.6 million in Q2 2023.
• A 5-year average of $378.8 million and a median of $408.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity tumbled 31.47%; it then soared 321.92% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $149.3 million in 2022, then surged by 68.84% to $252.1 million in 2023, then jumped by 81.68% to $457.9 million in 2024, then soared by 76.46% to $808.1 million in 2025, then slipped by 16.92% to $671.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $671.3 million in Q2 2026, $732.5 million in Q1 2026, and $808.1 million in Q4 2025.